Novo Nordisk

Novo Nordisk to present new cardiometabolic disease data, including results from SELECT, at the annual American Heart Association Scientific Sessions

Retrieved on: 
Tuesday, November 7, 2023
Science, Heart failure, Quality of life, Treatment, Comorbidity, Novo Nordisk, Diabetes, American Heart Association, Doctor of Philosophy, Research, Drug development, Risk, Partnership, Abstract, STEP, AWARE, Phenotype, SELECT, AHA, Nordisk, Pharmaceutical industry, Obesity

Results will be presented at the upcoming American Heart Association's (AHA) annual Scientific Sessions in Philadelphia, Pennsylvania from November 11-13, 2023.

Key Points: 
  • Results will be presented at the upcoming American Heart Association's (AHA) annual Scientific Sessions in Philadelphia, Pennsylvania from November 11-13, 2023.
  • Late-breaking scientific abstracts will be posted online at the exact date and time the embargo lifts.
  • Data from the SELECT trial will be presented live during a late-breaking science session at 8:30-9:15 AM EST on November 11.
  • As expected, there is significant risk with drug development and no guarantee that future studies will reflect similar results as presented at AHA.

Genevant Sciences to Collaborate with Novo Nordisk to Develop Gene Editing Treatment for Hemophilia A

Retrieved on: 
Monday, November 6, 2023
Gene editing, Carla Geneve, Haemophilia, Therapy, RNA, Megat Burhainuddin, Novo Nordisk, Exercise, Gene, LNP, Vaccine

VANCOUVER, British Columbia, and BASEL, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and an expansive lipid nanoparticle (LNP) patent portfolio, today announced that it has entered into a collaboration and nonexclusive license agreement with Novo Nordisk to combine Genevant’s proprietary LNP technology with innovative mRNA-based megaTAL technology to develop an in vivo gene editing treatment for hemophilia A. Genevant’s collaboration with Novo Nordisk builds upon a joint research and development collaboration in hemophilia A between Novo Nordisk and 2seventy bio previously announced by 2seventy bio.

Key Points: 
  • VANCOUVER, British Columbia, and BASEL, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and an expansive lipid nanoparticle (LNP) patent portfolio, today announced that it has entered into a collaboration and nonexclusive license agreement with Novo Nordisk to combine Genevant’s proprietary LNP technology with innovative mRNA-based megaTAL technology to develop an in vivo gene editing treatment for hemophilia A. Genevant’s collaboration with Novo Nordisk builds upon a joint research and development collaboration in hemophilia A between Novo Nordisk and 2seventy bio previously announced by 2seventy bio.
  • “We are thrilled to work with Novo Nordisk in the development of a potentially transformative gene editing treatment for a patient population in need of novel therapeutic approaches,” said Pete Lutwyche, Ph.D., President and Chief Executive Officer of Genevant Sciences.
  • The agreement announced today arises from the exercise of an option under a prior agreement between Genevant and 2seventy bio and subsequently assigned by 2seventy bio to Novo Nordisk.
  • The financial terms of the agreement are in accordance with the option agreement negotiated between Genevant and 2seventy bio and as announced by 2seventy bio in January 2022.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM

Retrieved on: 
Sunday, November 5, 2023
FDA, Novo Nordisk, News, Diabetes, CRRT, Hemofiltration, Chronic kidney disease, Pomerantz, LLP, Marketing, Health, Letter, Pharmaceutical industry

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).

Key Points: 
  • NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Outset and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM

Retrieved on: 
Friday, October 27, 2023
FDA, Novo Nordisk, News, Diabetes, CRRT, Hemofiltration, Chronic kidney disease, Pomerantz, LLP, Marketing, Health, Letter, Pharmaceutical industry

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).

Key Points: 
  • NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Outset and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

EMIS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Emisphere Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Thursday, November 2, 2023
Class Action Lawsuit, Professional Services, Legal, Person, Court, Mergers and acquisitions, Complaint, EMIS, Action, Novo Nordisk

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Emisphere Technologies, Inc. (“Emisphere” or “the Company”) (OTCMKTS: EMIS) and certain of its officers.

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Emisphere Technologies, Inc. (“Emisphere” or “the Company”) (OTCMKTS: EMIS) and certain of its officers.
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/emis .
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Amyloid, Survival, FDA, Bristol Myers Squibb, Research, Organ dysfunction, AD, IND, PD, Food, VITAL, ATTR, Therapy, Fast track (FDA), AL, Mortality, G&A, Novo Nordisk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Acquisition, European Medicines Agency, American Society of Hematology, MAD, SAD, Orphan, R, TTR, ASH, Clinical trial, Biology, Risk, Alpha-synuclein, Epitope, Amyloidosis, Society, SPA, Patient, Failure, Pharmaceutical industry, Vaccine, Fine chemical, Security (finance), Blood

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2023 and provided business highlights.

Key Points: 
  • Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2023 and provided business highlights.
  • Robust reduction of brain amyloid plaque has been demonstrated to likely predict clinical benefit for people with early AD.
  • The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for PRX012 for the treatment of AD.
  • As of September 30, 2023, Prothena had $673.1 million in cash, cash equivalents and restricted cash, and no debt.

Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics

Retrieved on: 
Monday, October 30, 2023
Oncology, Medical Devices, Health, Other Health, Radiology, Biotechnology, Senior, Conditional sentence, Novo Nordisk, Therapy, Pharmaceutical industry

Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo Nordisk A/S.

Key Points: 
  • Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo Nordisk A/S.
  • This agreement provides Novo Nordisk with worldwide, exclusive license to use Vect-Horus platform technology ”VECTrans”; for delivery of cargos directed against specified targets .
  • Novo Nordisk has an option to add additional targets to the license.
  • We look forward to collaborating with Novo Nordisk to unlock the potential of our technology platform and develop more efficient treatments”.

Team Novo Nordisk confirms 20-rider roster for the upcoming 2024 season

Retrieved on: 
Monday, October 30, 2023
Tour de la Mirabelle, TNN, 2021 Dwars door het Hageland, Novo Nordisk, Diabetes, 2017 Tour de Hongrie, GP Kranj, Matyas, European, Season, 2016 Crescent Vårgårda UCI Women's WorldTour, Team, Team Novo Nordisk, Consistency, 2013 Speedway European Championship, Tourism, Scheldeprijs, U23

ATLANTA, Oct. 30, 2023 /PRNewswire-PRWeb/ -- The world's first all diabetes professional cycling team today announced its 20-rider roster for the upcoming 2024 season with four exciting new signings and 16 renewals set to continue the Team Novo Nordisk mission to drive change in diabetes around the world.

Key Points: 
  • The world's first all diabetes professional cycling team today announced four exciting new signings and 16 renewals for the 2024 season.
  • ATLANTA, Oct. 30, 2023 /PRNewswire-PRWeb/ -- The world's first all diabetes professional cycling team today announced its 20-rider roster for the upcoming 2024 season with four exciting new signings and 16 renewals set to continue the Team Novo Nordisk mission to drive change in diabetes around the world.
  • "With consistent, positive results across the whole season, 2023 was arguably our best in the history of Team Novo Nordisk," began General Manager Vassili Davidenko.
  • Team Novo Nordisk for 2024:

Orexo announces changes in the company´s Board of Directors

Retrieved on: 
Friday, October 27, 2023
Vaccine, Novo Nordisk, Wyeth, Protein, Drug development, Senior, Pfizer, Robin, ORX, Extraordinary general meeting, Orexo, Committee, Novo Holdings A/S, Fine chemical

), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.
  • Robin Evers replaces Henrik Kjaer Hansen, who has announced he will resign after having represented Orexo´s largest shareholder, Novo Holdings A/S, since 2018.
  • Henrik Kjaer Hansen will continue to work closely with Orexo as chairman of Orexo´s.
  • James Noble, Chairman of the Board of Directors, said: "Orexo has a strong track record of developing new drugs that have been approved in markets all over the world.

Orexo announces changes in the company´s Board of Directors

Retrieved on: 
Friday, October 27, 2023
Vaccine, Novo Nordisk, Wyeth, Protein, Drug development, Senior, Pfizer, Robin, ORX, Extraordinary general meeting, Orexo, Committee, Novo Holdings A/S, Fine chemical

), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY), announces that Robin Evers, Senior Vice President, Head of Global Regulatory Affairs & Global Safety, Medical Writing and R&D Quality, at Novo Nordisk A/S has become a member of the company´s Board of Directors.
  • Robin Evers replaces Henrik Kjaer Hansen, who has announced he will resign after having represented Orexo´s largest shareholder, Novo Holdings A/S, since 2018.
  • Henrik Kjaer Hansen will continue to work closely with Orexo as chairman of Orexo´s.
  • James Noble, Chairman of the Board of Directors, said: "Orexo has a strong track record of developing new drugs that have been approved in markets all over the world.